IL-1β在酒精性肝病发病机制中的作用

全卉; 江宇泳

doi:10.3969/j.issn.1001-5256.2021.05.053

IL-1β在酒精性肝病发病机制中的作用

DOI: 10.3969/j.issn.1001-5256.2021.05.053

全卉^{1, 2},
江宇泳^1, ,

1.
首都医科大学附属北京地坛医院中西医结合中心，北京 100011
2.
北京中医药大学研究生院，北京 100011

基金项目:

北京中医药科技基金 (JJ2018-44);

首都卫生发展基金 (首发2020-2-2172)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：全卉负责查找文献，资料分析，撰写论文；江宇泳负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

作者简介:
全卉(1996—)，女，主要从事肝脏疾病相关研究

通信作者:
江宇泳，jyuy11@126.com

中图分类号: R575
计量
- 文章访问数: 523
- HTML全文浏览量: 80
- PDF下载量: 44
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-11
- 录用日期: 2020-12-14
- 出版日期: 2021-05-20

Role of interleukin-1β in the pathogenesis of alcoholic liver disease

Hui QUAN^{1, 2},
Yuyong JIANG^{1
, ,}

1.
Department of Integrated Traditional Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100011, China
2.
Graduate School of Beijing University of Chinese Medicine, Beijing100011, China

摘要

摘要: 酒精性肝病(ALD)已成为我国仅次于病毒性肝病的第二大肝病，慢性酒精暴露增加了IL-1β等促炎因子的产生，其与酒精性肝炎的主要症状如发热、白细胞增加密切相关。介绍了IL-1β的产生和功能；在ALD中通过对肝实质细胞与非实质细胞的作用推进肝脂肪变性和炎症，通过调控肝星状细胞的增殖来加速肝纤维化，指出通过干扰IL-1β的途径可能成为未来治疗ALD的策略之一。
- 肝疾病, 酒精性 /
- 脂肪肝, 酒精性 /
- 白细胞介素1β
Abstract: Alcoholic liver disease (ALD) has become the second largest liver disease after viral liver disease in China. Chronic alcohol exposure increases the production of proinflammatory factors including interleukin-1β (IL-1β), which is closely associated with the main symptoms of alcoholic hepatitis such as pyrexia and elevated white blood cell count. This article introduces the production and function of IL-1β; in ALD, it promotes hepatic steatosis and inflammation by acting on liver parenchymal cells and nonparenchymal cells and accelerates liver fibrosis by regulating the proliferation of hepatic stellate cells. It is pointed out that interference with the IL-1β pathway may become one of the treatment strategies for ALD in the future.
- Liver Diseases, Alcoholic /
- Fatty Liver, Alcoholic /
- Interleukin-1beta

HTML全文

参考文献(35)

[1]	XIE YD, ZHAO CQ, WANG JP, et al. Alcohol consumption analysis among patients with liver disease in China[J]. Chin Med J (Engl), 2019, 132(4): 420-430. DOI: 10.1097/CM9.0000000000000067.
[2]	IPSEIZ N, PICKERING RJ, ROSAS M, et al. Tissue-resident macrophages actively suppress IL-1beta release via a reactive prostanoid/IL-10 pathway[J]. EMBO J, 2020, 39(14): e103454. DOI: 10.15252/embj.2019103454.
[3]	MUÑOZ-PLANILLO R, KUFFA P, MARTÍNEZ-COLÓN G, et al. K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter[J]. Immunity, 2013, 38(6): 1142-1153. DOI: 10.1016/j.immuni.2013.05.016.
[4]	TALTY A, DEEGAN S, LJUJIC M, et al. Inhibition of IRE1α RNase activity reduces NLRP3 inflammasome assembly and processing of pro-IL1β[J]. Cell Death Dis, 2019, 10(9): 622. DOI: 10.1038/s41419-019-1847-z.
[5]	BUSCETTA M, di VINCENZO S, MIELE M, et al. Cigarette smoke inhibits the NLRP3 inflammasome and leads to caspase-1 activation via the TLR4-TRIF-caspase-8 axis in human macrophages[J]. FASEB J, 2020, 34(1): 1819-1832. DOI: 10.1096/fj.201901239R.
[6]	KARMAKAR M, MINNS M, GREENBERG EN, et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis[J]. Nat Commun, 2020, 11(1): 2212. DOI: 10.1038/s41467-020-16043-9.
[7]	JAKKA P, NAMANI S, MURUGAN S, et al. The Brucella effector protein TcpB induces degradation of inflammatory caspases and thereby subverts non-canonical inflammasome activation in macrophages[J]. J Biol Chem, 2017, 292(50): 20613-20627. DOI: 10.1074/jbc.M117.815878.
[8]	RV HL S, BROZ P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux[J]. Eur J Immunol, 2015, 45(10): 2927-2936. DOI: 10.1002/eji.201545772.
[9]	MAHMUTOVIC PERSSON I, MENZEL M, RAMU S, et al. IL-1β mediates lung neutrophilia and IL-33 expression in a mouse model of viral-induced asthma exacerbation[J]. Respir Res, 2018, 19(1): 16. DOI: 10.1186/s12931-018-0725-z.
[10]	DING Z, WANG X, LIU S, et al. NLRP3 inflammasome via IL-1β regulates PCSK9 secretion[J]. Theranostics, 2020, 10(16): 7100-7110. DOI: 10.7150/thno.45939.
[11]	MANDREKAR P, SZABO G. Signalling pathways in alcohol-induced liver inflammation[J]. J Hepatol, 2009, 50(6): 1258-1266. DOI: 10.1016/j.jhep.2009.03.007.
[12]	ZHAO J, QI YF, YU YR. Research advances in the role of oxidative stress in the development and progression of liver fibrosis[J]. J Clin Hepatol, 2019, 35(9): 2067-2071. DOI: 10.3969/j.issn.1001-5256.2019.09.040. 赵杰, 齐永芬, 鱼艳荣. 氧化应激在肝纤维化发生发展中的作用[J]. 临床肝胆病杂志, 2019, 35(9): 2067-2071. DOI: 10.3969/j.issn.1001-5256.2019.09.040.
[13]	AL-SADI R, GUO S, YE D, et al. Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation[J]. J Immunol, 2013, 190(12): 6596-6606. DOI: 10.4049/jimmunol.1201876.
[14]	PETRASEK J, BALA S, CSAK T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice[J]. J Clin Invest, 2012, 122(10): 3476-3489. DOI: 10.1172/JCI60777.
[15]	STIENSTRA R, SAUDALE F, DUVAL C, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity[J]. Hepatology, 2010, 51(2): 511-522. DOI: 10.1002/hep.23337.
[16]	GLUCHOWSKI NL, GABRIEL KR, CHITRAJU C, et al. Hepatocyte deletion of triglyceride-synthesis enzyme acyl coA: Diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice[J]. Hepatology, 2019, 70(6): 1972-1985. DOI: 10.1002/hep.30765.
[17]	STANTON MC, CHEN SC, JACKSON JV, et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice[J]. J Inflamm (Lond), 2011, 8: 8. DOI: 10.1186/1476-9255-8-8.
[18]	IRACHETA-VELLVE A, PETRASEK J, SATISHCHANDRAN A, et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice[J]. J Hepatol, 2015, 63(5): 1147-1155. DOI: 10.1016/j.jhep.2015.06.013.
[19]	CUI K, YAN G, XU C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice[J]. J Hepatol, 2015, 62(6): 1311-1318. DOI: 10.1016/j.jhep.2014.12.027.
[20]	ILYAS G, CINGOLANI F, ZHAO E, et al. Decreased macrophage autophagy promotes liver injury and inflammation from alcohol[J]. Alcohol Clin Exp Res, 2019, 43(7): 1403-1413. DOI: 10.1111/acer.14041.
[21]	WANG H, ZHOU H, ZHANG Q, et al. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice[J]. J Hepatol, 2020, 73(6): 1470-1481. DOI: 10.1016/j.jhep.2020.07.016.
[22]	LEE J H, SHIM Y R, SEO W, et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through toll-like receptor 3 in alcoholic liver injury[J]. Hepatology, 2020, 72(2): 609-625. DOI: 10.1002/hep.31041.
[23]	PETRASEK J, DOLGANIUC A, CSAK T, et al. Type interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice[J]. Gastroenterology, 2011, 140(2): 697-708. e4. DOI: 10.1053/j.gastro.2010.08.020.
[24]	GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041.
[25]	ALEGRE F, PELEGRIN P, FELDSTEIN A. Inflammasomes in liver fibrosis[J]. Seminars in liver disease, 2017, 37(2): 119-127. DOI: 10.1055/s-0037-1601350.
[26]	REITER FP, WIMMER R, WOTTKE L, et al. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model[J]. World J Hepatol, 2016, 8(8): 401-410. DOI: 10.4254/wjh.v8.i8.401.
[27]	YAPING Z, YING W, LUQIN D, et al. Mechanism of interleukin-1β-induced proliferation in rat hepatic stellate cells from different levels of signal transduction[J]. APMIS, 2014, 122(5): 392-398. DOI: 10.1111/apm.12155.
[28]	PRADERE JP, KLUWE J, de MINICIS S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J]. Hepatology, 2013, 58(4): 1461-1473. DOI: 10.1002/hep.26429.
[29]	KAMARI Y, SHAISH A, VAX E, et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice[J]. J Hepatol, 2011, 55(5): 1086-1094. DOI: 10.1016/j.jhep.2011.01.048.
[30]	DINARELLO CA, SIMON A, van DER MEER JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases[J]. Nat Rev Drug Discov, 2012, 11(8): 633-652. DOI: 10.1038/nrd3800.
[31]	SZABO G, PETRASEK J, BALA S. Innate immunity and alcoholic liver disease[J]. Dig Dis, 2012, 30(Suppl 1): 55-60. DOI: 10.1159/000341126.
[32]	GEHRKE N, HÖVELMEYER N, WAISMAN A, et al. Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation[J]. J Hepatol, 2018, 68(5): 986-995. DOI: 10.1016/j.jhep.2018.01.008.
[33]	SHIRASUGI N, WAKABAYASHI G, SHIMAZU M, et al. Up-regulation of oxygen-derived free radicals by interleukin-1 in hepatic ischemia/reperfusion injury[J]. Transplantation, 1997, 64(10): 1398-1403. DOI: 10.1097/00007890-199711270-00004.
[34]	RIDKER PM, MACFADYEN JG, THUREN T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, 390(10105): 1833-1842. DOI: 10.1016/S0140-6736(17)32247-X.
[35]	DHIMOLEA E. Canakinumab[J]. MAbs, 2010, 2(1): 3-13. DOI: 10.4161/mabs.2.1.10328.